Comment from Friends of Cancer Research

Summary: Friends of Cancer Research supports the draft guidance as an important step toward clarifying the plausible mechanism framework for individualized therapies. They request additional clarity on CMC expectations, definitions for "well-characterized" natural history data, assay standardization for platform trials, and strategies for data leveraging across product variants.